Pharma

Union health ministry approves new treatment for multi-drug resistant TB

The Union health ministry has approved the introduction of the BPaLM regimen, a novel treatment for multi-drug resistant tuberculosis (MDR-TB) under its National TB Elimination Program (NTEP) as a highly effective and shorter treatment option. This regimen includes a new anti-TB drug namely Pretomanid in combination with Bedaquiline and Linezolid (with or without Moxifloxacin), the ministry said in a statement.\ Pretomanid has earlier been approved and licensed for use in India by the Central Drugs Standard Control Organization (CDSCO). The BPaLM regimen, which consists four-drug combination -- Bedaquiline, Pretomanid, Linezolid and Moxifloxacin -- has been proven to be safe, more effective and a quicker treatment option than the previous MDR-TB treatment procedure, the ministry said. "While traditional MDR-TB treatments can last up to 20 months with severe side effects, BPaLM regimen can cure the drug-resistant TB in just six months with a high treatment success rate," the stateme

Indian pharma market registers over 6% growth in July '24: Pharmarack

"Seasonality-driven molecules and molecular combinations, especially anti-infectives, have shown a relatively stronger volume-driven growth," the firm stated in its report

USAID, Takeda Biopharma launch dengue prevention programme across India

The vaccine is already available for children and adults in the private market in Europe, Indonesia, and Thailand, and in some public programmes in Argentina and Brazil

Lupin stock hits eight-year high at Rs 1,749 on healthy earnings outlook

Firm has a bunch of products lined up which will ensure limited earnings dip in FY27: Analysts

Pharma industry body mulling policy framework to guide cos on cybercrime

The Indian pharma companies are better off in terms of facing cyber-attacks now as compared to a few years ago

Pricing challenge in US biz, rich valuations may weigh on pharma stocks

Among individual players, Aurobindo Pharma, Dr Reddys Labs, and Zydus Lifesciences sourced 48 per cent, 47 per cent, and 46 per cent of their total revenues from the US generics segment, respectively

Gland Pharma surges 11% amidst stellar Q4 results; profits grow two fold

On Wednesday, Gland Pharma reported a two fold jump or 145 per cent increase in consolidated net profit, reaching Rs 192.4 crore for the January-March period of FY24

Promoter of Granules India sells 3.09% stake for Rs 304 cr via open market

Krishna Prasad Chigurupati, one of the promoters of Granules India, on Wednesday pared a 3.09 per cent stake in the company for Rs 304 crore through an open market transaction. According to the block deal data available on the NSE, Krishna Prasad Chigurupati offloaded 75 lakh shares, amounting to a 3.09 per cent stake in Granules India. The shares were disposed of at an average price of Rs 405.08 apiece, taking the deal size to Rs 303.81 crore, as per the data on the National Stock Exchange (NSE). According to a regulatory filing on Wednesday, Granules India said the primary objectives of the deal was to clear personal debt, to release the existing pledge on his holding in the company, and creating a small personal liquidity. "Chigurupati further notified the company that he has no plans to sell his shareholding in Granules India Ltd in the foreseeable future. "Post this transaction, the total promoter & promoter group shareholding in the company has changed from 41.96 per cent to

Sun Pharma Q4 Preview: Profits may grow up to 41% on higher specialty sales

Sun Pharma is set to see a strong financial earnings on a year-on-year (Y-o-Y) basis for Q4FY23, showing a 8-14 per cent Y-o-Y jump in its topline

Cipla Q4 Results Preview: Profits may jump up to 75% on higher volumes

Cipla may show a 3-10 per cent jump in its topline year-on-year (Y-o-Y), registering revenues in the range of Rs 5,939 crore and Rs 6,292 crore

Dr Reddy's Labs slumps 5% as brokerages give 'Reduce' call post Q4 earnings

The miss was driven by lower Revlimid sales, muted growth across markets and higher R&D spends. While the prevailing US tailwinds provide stability, absence of any meaningful approvals for Dr Reddy's

Q4 Results Preview: Lupin may see strong topline, bottomline growth

Indian pharmaceutical major Lupin is set to witness a strong financial earnings on a year-on-year (Y-o-Y) basis for the fourth quarter of the financial year 2023-24 (Q4FY23)

Morgan Stanley PE, India Life Sciences Fund inject Rs 1,000 cr into Maiva

Maiva Pharma on Thursday said it has raised Rs 1,000 crore from Morgan Stanley Private Equity Asia and India Life Sciences Fund. The transaction includes both primary and secondary funding, the Bengaluru-based pure play injectables contract development and manufacturing organisation said. The two investors have jointly acquired a controlling stake from existing investors and also infused primary capital into the company, an official statement said, without disclosing the stakes picked up. This is Maiva's first private equity fundraise and the proceeds will be used to set up a new manufacturing facility near Karnataka's Hosur with capabilities in sterile dosage forms, including pre-filled syringes, bags, oncology, and hormonal injectables. It already has a facility in Hosur approved by the USFDA and other regulators that manufacture vials. "This fundraise will be used to add more vial, lyophilisation, and suspension capacity and introduce new manufacturing capabilities such as ...

Ayurveda products market in India to reach Rs 1.2 trillion by FY28: Report

India's Ayurveda product market is projected to reach USD 16.27 billion or Rs 1.2 lakh crore by FY28 from USD 7 billion or Rs 57,450 crore at present, according to a study. Ayurveda product market has experienced significant growth due to rising demand for natural and herbal remedies in local and international markets, increase in ayurvedic medical practitioners, government initiatives, and emergence of new entrepreneurs, Ayurveda tech startup NirogStreet said. Citing a survey, NirogStreet said the Ayurveda product market in India is expected to grow significantly, with projections indicating a substantial increase in market value to Rs 1,20,660 crore (USD 16.27 billion) by FY28. According to NirogStreet survey, the overall market for Ayurveda products and services is expected to grow at a CAGR of 15 per cent from FY23 to FY28, with the product and service sectors growing at a CAGR of 16 per cent and 12.4 per cent, respectively. The survey also estimated the value of the country's

Explosion at Telangana pharma plant kills director, 3 workers; 16 injured

Four persons were killed and 16 others injured due to an explosion in a chemical reactor at a pharmaceutical company's plant in Sangareddy district of Telangana on Wednesday, police and fire department officials said, adding that among the deceased is the firm's director. The blast occurred around 5 pm at the factory of SB Organics Ltd, located at Chandapur village of Hathnoora mandal of the district, and it led to a fire, they said. The plant is located about 40 km from Hyderabad International airport. The fire, which spread through the pharma unit's premises, was subsequently brought under control, the officials said. The deceased include the pharma firm's director and three workers, police said, but further details about the deceased were not immediately available. "The reactor exploded at the pharma company and people around it were thrown away in its impact...Four people have died," a senior police official told PTI. Sixteen others who suffered injuries in the incident have

AstraZeneca bets on next-generation cancer therapy with $2 bn Fusion deal

AstraZeneca will pay $21 per Fusion share, a premium of more than 97% to the US-listed company's closing price on Monday

CAPFIMS signs MoU with Aiims to run it as campus, MHA will provide funding

The Central Armed Police Forces Institute of Medical Sciences (CAPFIMS) on Saturday signed an MoU with the AIIMS to run CAPFIMS as a campus of the AIIMS here. The funds for procurement of medical equipment and furniture and the recurring cost towards operations and maintenance of the campus shall be provided to the All India Institute of Medical Sciences (AIIMS) by the Ministry of Home Affairs, an official statement said. Further, a part of the hospital beds in the campus shall be earmarked for providing healthcare services to all Central Armed Police Forces (CAPF) beneficiaries. The Union Cabinet has approved budgetary support of Rs 2,207.50 crore in the 15th Finance Commission cycle to run the CAPFIMS as a campus of AIIMS, New Delhi. Under the leadership of Prime Minister Narendra Modi, enhancing healthcare infrastructure in the country and providing world class health facilities to the people is one of the priorities of the government of India, the statement said. The MHA, unde

Billionaires spending a fortune to lure scientists away from universities

Braggadocio from startups is de rigueur, and plenty of ex-academics have started biotechnology firms, hoping to strike it rich on their one big discovery

Indian companies likely to garner up to 50% USFDA nod share in 2023

Companies may get up to 375 ANDA approvals in 2023, more than last year's 355

Indian pharma firm recalls 27 types of eyedrops in US made for CVS, Walmart

The Food and Drug Administration warned consumers last month not to purchase or use store-brand eyedrops from Walmart Inc., CVS Health Corp., Target Corp. and other companies